Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial

• Published in: Clinical lung cancer 2024-03, Vol.25 (2), p.186-189
• Main Authors: Hui, Caressa, Brown, Eleanor, Wong, Samantha, Das, Millie, Wakelee, Heather, Neal, Joel, Ramchandran, Kavitha, Myall, Nathaniel J., Pham, Daniel, Xing, Lei, Yang, Yong, Kovalchuk, Nataliya, Yuan, Ying, Lu, Ying, Xiang, Michael, Chin, Alex, Diehn, Maximilian, Loo, Billy W., Vitzthum, Lucas K.
• Format: Article
• Language: English
• Subjects: Adolescent; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bayes Theorem; Carcinoma, Non-Small-Cell Lung - drug therapy; Chemoradiotherapy - methods; Clinical trial; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose escalation; Humans; Isotoxic radiation; Lung; Lung Neoplasms - drug therapy; Personalized medicine; Personalized radiation
• ISSN: 1525-7304; 1938-0690; 1938-0690
• DOI: 10.1016/j.cllc.2023.11.004

Prior attempts to escalate radiation dose for non–small cell lung cancer (NSCLC) have not improved survival. Given the high risk for cardiopulmonary toxicity with treatment and heterogenous presentation of locally advanced NSCLC, it is unlikely that a single dose regimen is optimal for all patients. This phase I/II trial aims to evaluate a novel treatment approach where the level of accelerated hypofractionation is determined by the predicted toxicity from dose to organs at risk (OARs). Patients ≥ 18 years old with lung cancer planned for fractionated radiotherapy to the lung with concurrent chemotherapy will be eligible. Radiation therapy (RT) will be delivered to a total dose of 60 to 66 Gy in 30, 25, or 20 fractions depending on the ability to meet constraints to key organs at risk including the lungs, heart, and esophagus. The primary endpoint is high grade pulmonary, esophageal, or cardiac toxicity. A Bayesian optimized design is used to determine stopping boundaries and evaluate the primary endpoint. PACER will evaluate the safety and feasibility of personalized accelerated chemoradiotherapy for lung cancer.